Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin
OwnerKwok S. Yu, Ziyang Zhonginventors
Life of this patent
Estimating the term…
Abstract
A pharmaceutical formulation comprising (a) 17-allylamino-17-demethoxy-geldanamycin; (b) an ester of d-α-tocopheryl succinate and polyethylene glycol; and (c) a pharmaceutically acceptable, water-miscible organic solvent.
Claims26
A pharmaceutical formulation comprising (a) 17-allylamino-17-demethoxy-geldanamycin (“17-AAG”);
- (b) an ester of d-α-tocopheryl succinate and polyethylene glycol;
- and (c) a pharmaceutically acceptable, water-miscible organic solvent.
A method for preparing a 17-allylamino-17-demethoxygeldanamycin (“17-AAG”) pharmaceutical formulation ready for administration to a subject, comprising the steps of:
- (i) providing a pharmaceutical formulation comprising (a) 17-AAG;
- (b) an ester of d-α-tocopheryl succinate and polyethylene glycol;
- and (c) a pharmaceutically acceptable, water-miscible organic solvent;
- and
- (ii) diluting the pharmaceutical formulation with a pharmaceutically acceptable aqueous medium to produce a diluted pharmaceutical formulation ready for administration to a subject.
A method for administering 17-allylamino-17-demethoxygeldanamycin (“17-AAG”) to a subject, comprising the steps of:
- (i) providing a pharmaceutical formulation comprising (a) 17-AAG;
- (b) an ester of d-α-tocopheryl succinate and polyethylene glycol;
- and (c) a pharmaceutically acceptable, water-miscible organic solvent;
- (ii) diluting the pharmaceutical formulation with a pharmaceutically acceptable aqueous medium to produce a diluted pharmaceutical formulation;
- and
- (iii) administering the diluted pharmaceutical formulation to a subject.
A method for preparing a 17-allylamino-17-demethoxygeldanamycin (“17-AAG”) pharmaceutical formulation ready for administration to a subject, comprising the steps of:
- (i) providing a mixture of 17-AAG and an ester of d-α-tocopheryl succinate and polyethylene glycol;
- (ii) dissolving the mixture of 17-AAG and an ester of d-α-tocopheryl succinate and polyethylene glycol in a pharmaceutically acceptable, water-miscible organic solvent to produce a pharmaceutical formulation;
- and
- (iii) diluting the pharmaceutical formulation with a pharmaceutically acceptable aqueous medium to produce a diluted pharmaceutical formulation ready for administration to a subject.
A method for administering 17-allylamino-17-demethoxygeldanamycin (“17-AAG”) to a subject, comprising the steps of:
- (i) providing a mixture of 17-AAG and an ester of d-α-tocopheryl succinate and polyethylene glycol;
- (ii) dissolving the mixture of 17-AAG and an ester of d-α-tocopheryl succinate and polyethylene glycol in a pharmaceutically acceptable, water-miscible organic solvent to produce a pharmaceutical formulation;
- (iii) diluting the pharmaceutical formulation with a pharmaceutically acceptable aqueous medium to produce a diluted pharmaceutical formulation;
- and
- (iv) administering the diluted pharmaceutical formulation to a subject.
A kit comprising 17-allylamino-17-demethoxygeldanamycin (“17-AAG”), an ester of d-α-tocopheryl succinate and polyethylene glycol, and a pharmaceutically acceptable, water-miscible organic solvent.
Dependencies are inferred from the claim text.